BridgeBio Pharma (BBIO) EV/EBIT: History & Chart

BridgeBio Pharma, Inc.(BBIO)

Biotechnology · Palo Alto, CA

$66.14-1.11 (-1.65%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Palo Alto, CA

999 employees

www.bridgebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neil Kumar

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
BridgeBio Pharma, Inc. (BBIO)	$12.95B	N/A	N/A	N/A	N/A
ICON Public Limited Company (ICLR)vs ›	$12.89B	18.45x	15.92x	20.76x	30.03x
Corcept Therapeutics Incorporated (CORT)vs ›	$13.19B	2043.65x	598.71x	197.00x	123.59x
Baxter International Inc. (BAX)vs ›	$12.52B	N/A	440.49x	243.05x	134.16x
Penumbra, Inc. (PEN)vs ›	$12.49B	66.71x	68.46x	853.99x	925.32x
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.17B	29.29x	39.06x	51.84x	51.84x
Encompass Health Corporation (EHC)vs ›	$12.00B	13.19x	13.17x	11.44x	11.49x
Ascendis Pharma A/S (ASND)vs ›	$14.16B	109.12x	130.84x	130.84x	130.84x
DaVita Inc. (DVA)vs ›	$11.47B	10.23x	12.03x	12.60x	12.96x
Bio-Techne Corporation (TECH)vs ›	$11.36B	45.21x	74.68x	59.09x	57.11x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

BridgeBio Pharma, Inc. (BBIO)

$12.95B

N/A

ICON Public Limited Company (ICLR)vs ›

$12.89B

18.45x

15.92x

20.76x

30.03x

Corcept Therapeutics Incorporated (CORT)vs ›

$13.19B

2043.65x

598.71x

197.00x

123.59x

Baxter International Inc. (BAX)vs ›

$12.52B

N/A

440.49x

243.05x

134.16x

Penumbra, Inc. (PEN)vs ›

$12.49B

66.71x

68.46x

853.99x

925.32x

BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›

$12.17B

29.29x

39.06x

51.84x

Encompass Health Corporation (EHC)vs ›

$12.00B

13.19x

13.17x

11.44x

11.49x

Ascendis Pharma A/S (ASND)vs ›

$14.16B

109.12x

130.84x

DaVita Inc. (DVA)vs ›

$11.47B

10.23x

12.03x

12.60x

12.96x

Bio-Techne Corporation (TECH)vs ›

$11.36B

45.21x

74.68x

59.09x

57.11x

EV/EBIT Ratio: N/A

BBIO EV/EBIT Ratio Metrics

BBIO Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics